Technology Networks

NOXXON Pharma AG

Max-Dohrn-Str. 8-10,
D-10589 Berlin
Germany
Tel: +49 (0)30 / 72 62 47-0
Fax: +49 (0)30 / 72 62 47-225

Print Email to a friend

NOXXON Pharma AG is a biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology.

Further Information: http://www.noxxonpharma.com/


Related news from our archive

NOXXON Initiates First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.

NOXXON Pharma AG Announces Preliminary Phase I Trial Results for Spiegelmer® NOX-E36
The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of the chemokine inhibitor NOX-E36 in 72 healthy volunteers.

NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12
The 1.7 million US$ will be used for the impending phase I clinical development of company’s candidate Spiegelmer® NOX-A12.

NOXXON Initiates First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.

NOXXON Pharma AG Announces Preliminary Phase I Trial Results for Spiegelmer® NOX-E36
The phase I study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of the chemokine inhibitor NOX-E36 in 72 healthy volunteers.

NOXXON is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer® NOX-A12
The 1.7 million US$ will be used for the impending phase I clinical development of company’s candidate Spiegelmer® NOX-A12.